Results 101 to 110 of about 51,155 (263)

RNA‐binding protein RBMS1: A new target for cancer diagnosis and treatment

open access: yesPrecision Medical Sciences, EarlyView.
This schematic illustrates the diverse regulatory roles of RNA‐binding motif single‐stranded interacting protein 1 (RBMS1) across multiple human cancers. In breast cancer, RBMS1 stabilizes B4GALT1 mRNA to promote PD‐L1 glycosylation, modulating tumor immune escape and immunotherapy efficacy.
Xingda Run   +7 more
wiley   +1 more source

From cytokine storm to renal scarring in diabetic kidney disease: Biomarkers, risk stratification, and precision therapeutics

open access: yesPrecision Medical Sciences, EarlyView.
Hyperglycemia‐driven cytokine activation initiates a sustained inflammatory cascade in diabetic kidney disease, promoting cellular injury and fibrogenic signaling. Integrating cytokine‐based biomarkers with risk stratification enables precision therapeutics that target inflammation and fibrosis, ultimately aiming to halt progression from early renal ...
Emmanuel Ifeanyi Obeagu
wiley   +1 more source

Genomics and epigenomics of tissue repair: Implications for personalized medicine

open access: yesPrecision Medical Sciences, EarlyView.
Genomic and epigenomic mechanisms govern tissue repair and regeneration through dynamic regulation of inflammation, cell fate, and extracellular matrix remodeling. The integration of multi‐omics, artificial intelligence, and precision regenerative therapies enables biomarker‐driven, personalized approaches to enhance healing and minimize fibrosis ...
Jharna Medhi   +7 more
wiley   +1 more source

Synergistic effects and clinical utilization of radioimmunotherapy for brain metastases from driver mutation‐negative non‐small cell lung cancer

open access: yesPrecision Radiation Oncology, EarlyView.
This review summarizes how combining radiotherapy with immune checkpoint inhibitors overcomes the immunosuppressive brain microenvironment in non‐small cell lung cancer (NSCLC) brain metastases. The synergy enhances immune cell infiltration and systemic anti‐tumor activity, improving survival outcomes for patients.
Silai Yu   +7 more
wiley   +1 more source

Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 583-595, March 2025.
ABSTRACT Prior pharmacokinetic (PK) analysis revealed that increased alpha‐1‐acid glycoprotein (AAG) levels are associated with decreased imatinib unbound fraction in coronavirus disease 2019 (COVID‐19) patients. This study aimed to investigate the PK of total and unbound concentrations of imatinib and the metabolite N‐desmethyl imatinib in ...
Medhat M. Said   +10 more
wiley   +1 more source

Immunomodulatory Properties of Withania somnifera: Regulation of Innate Immune Cells and Clinical Implications

open access: yesPhytotherapy Research, EarlyView.
ABSTRACT Withania somnifera (L.) Dunal (WS), commonly known as Ashwagandha, is a prominent medicinal herb in Ayurveda, with extensive therapeutic potential attributed to its diverse phytochemical profile. This review critically examines the immunomodulatory properties of WS, focusing on innate immune cell populations, including neutrophils, eosinophils,
Rana Yukta   +9 more
wiley   +1 more source

Therapeutic Properties and Underlying Mechanisms of Traditional Chinese Medicine in Managing Rheumatoid Arthritis: An Integrative Review of Clinical and Molecular Findings

open access: yesPhytotherapy Research, EarlyView.
The translational research framework integrating TCM for RA. The figure outlines a stepwise framework for the modernization and clinical translation of TCM in RA. Part 1 highlights the inheritance and development of TCM theory, including classical medical texts, traditional herbal knowledge, and syndrome differentiation–based treatment principles. Part
Jianting Wen   +4 more
wiley   +1 more source

Refractory mogamulizumab-associated rash responding to an oral Janus kinase inhibitor

open access: yesJAAD Case Reports, 2023
Carine M. Lama, MS   +4 more
doaj   +1 more source

Type I interferon overactivation in sera of patients with anti‐MDA5‐positive dermatomyositis‐associated interstitial lung disease

open access: yesRheumatology &Autoimmunity, EarlyView.
Sera from patients with anti‐MDA5‐positive dermatomyositis‐associated interstitial lung disease (ILD) exhibit significantly higher type I interferon (IFN‐I) bioactivity and interferon‐stimulated gene‐inducing activity compared to anti‐ARS‐positive ILD and healthy controls.
Shohei Nakamura   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy